Latest news

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica’s three largest shareholders or owner groups in terms of voting rights as of September 30, 2026, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2027 Annual General Meeting. The nomination committee for Nanologica AB’s AGM 2027 thus consists of the following three members: Carl-Johan Spak (Flerie Invest

On October 23, 2026, Nanologica AB (publ) announced that Mark Quick has been appointed as the new CEO, provided that the Swedish Companies Registration Office grants an exemption from the requirement of residence in the EEA pursuant to Chapter 8, Section 30 of the Swedish Companies Act (2005:551). The Swedish Companies Registration Office has now granted an exemption, and Mark Quick has assumed the position as CEO. The exemption is valid until November 30, 2027,

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES OTHER THAN THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURE. SEE

Nanologica AB has updated its strategy focusing on accelerating commercial growth, broadening the offering, and increasing focus on North America and Europe. To lead the next phase of development, the Board of Directors has appointed Mark Quick as CEO of the Group. Current CEO Andreas Bhagwani will continue as General Manager of Nanologica’s purification and separation business with a primary focus on driving commercial expansion. The Board also intends to resolve to carry out a